苑东生物：亚甲蓝注射液获得美国FDA药品注册批准

Core Viewpoint - The company Yuandong Biotech announced that its wholly-owned subsidiary Chengdu Shode Pharmaceutical Co., Ltd. has received formal approval from the U.S. FDA for the Abbreviated New Drug Application (ANDA) for Methylene Blue Injection, which is indicated for the treatment of acquired methemoglobinemia in both children and adults [1] Group 1 - The active ingredient of Methylene Blue Injection is Methylene Blue [1] - According to IMS database statistics, the sales amount of Methylene Blue Injection in the U.S. market is approximately $30.24 million for the first three quarters of 2025 [1]